Bristol Myers Squibb

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

fouremm

Rank: President [?]

Points: 3330 [?]

Votes: 34 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Bristol Myers Squibb

posted on Aug 04, 2017 02:03PM

..... just spent up to $2.3B for preclinical IFM Therapeutics which has two immunotherapy cancer programs. $300MM upfront and up about $1B each for the two therapies depending on milestones met. Wonder what our little Zenith might be worth. Be nice to hear what is going on.

6 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply